Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 10/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 8/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18853997 | 0.91 | ALOX5AP (0.45) | FEN1ALOX5APMAP3K12AAK1 | |
| SCHEMBL15723937 | 0.83 | ALOX5AP (0.37) | FEN1ALOX5APAAK1 | |
| SCHEMBL27305756 | 0.75 | TRPM8 (0.37) | — | |
| SCHEMBL15731253 | 0.74 | ALOX5AP (0.52) | FEN1ALOX5APMAP3K12 | |
| SCHEMBL15723914 | 0.72 | PTPN5 (0.40) | — | |
| SCHEMBL15723953 | 0.71 | FEN1 (0.43) | FEN1ALOX5AP | |
| SCHEMBL14555874 | 0.71 | ALOX5AP (0.38) | FEN1ALOX5AP | |
| SCHEMBL799120 | 0.70 | MAP3K12 (0.37) | MAP3K12 | |
| SCHEMBL15723925 | 0.68 | MAP4K4 (0.50) | FEN1ALOX5AP | |
| SCHEMBL15724371 | 0.68 | FEN1 (0.45) | FEN1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | FEN1 2354/4885ALOX5AP 1825/4885MAP3K12 1616/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | FEN1 2354/4885ALOX5AP 1825/4885MAP3K12 1616/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | FEN1 2354/4885ALOX5AP 1825/4885MAP3K12 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.